$57.69 0.00 (%) Bristol-Myers Squibb Co - NYSE

Dec. 16, 2014 | 04:00 PM

Partner Headlines

  1. Meet 5 Top Biotech Stocks Holding Up In Shaky Market

    IBD | Dec. 13, 2014 | 08:02AM EST
  2. Celgene drug could gain share

    IBD | Dec. 11, 2014 | 19:00PM EST
  3. Celgene's Abraxane Succeeds In Early Breast Cancer

    IBD | Dec. 11, 2014 | 11:27AM EST
  4. Merck's Keytruda Might Treat Virulent Breast Cancer

    IBD | Dec. 10, 2014 | 11:04AM EST
  5. US Stock Futures Edge Lower Ahead Of Federal Budget

    Benzinga | Dec. 10, 2014 | 07:01AM EST
  6. T Rowe Price's Top Stakes for the Third Quarter

    GuruFocus | Dec. 9, 2014 | 10:16AM EST
  7. I think Zimmer Will Outperform S&P 500 Performance

    GuruFocus | Dec. 4, 2014 | 10:06AM EST
  8. Avanir Stock Jumps On $3.5 Billion Otsuka Buyout

    IBD | Dec. 2, 2014 | 11:22AM EST
  9. A Buy Recommendation From Absolute Valuation Model to Bristol-Myers Squibb

    GuruFocus | Nov. 24, 2014 | 13:05PM EST
  10. Screening Pharma Stocks Amid Turnaround

    YCharts | Nov. 19, 2014 | 09:37AM EST
  11. Incyte Building Blockbuster Drug One Disease At A Time

    IBD | Nov. 17, 2014 | 15:58PM EST
  12. Blackhill Bets Almost Half of Portfolio on Williams-Sonoma

    GuruFocus | Nov. 10, 2014 | 16:00PM EST
  13. Merck Down On Hepatitis C Data; Gilead Rises

    IBD | Nov. 10, 2014 | 11:14AM EST
  14. A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio

    GuruFocus | Nov. 9, 2014 | 18:16PM EST
  15. Dan Nathan Sees Unusual Options Activity In Bristol-Myers Squibb Co

    Benzinga | Oct. 31, 2014 | 07:49AM EST
  16. Lung cancer drug promising

    IBD | Oct. 30, 2014 | 19:14PM EST
  17. Bristol-Myers Lung-Cancer Drug Boosts Survival

    IBD | Oct. 30, 2014 | 11:31AM EST
  18. #PreMarket Primer: Monday, October 27: ECB Stress Tests In-Line With Expectations

    Benzinga | Oct. 27, 2014 | 08:19AM EST
  19. Eliquis revives Bristol-Myers

    IBD | Oct. 24, 2014 | 18:27PM EST
  20. Bristol-Myers Beats Q3 Views As Eliquis Revives

    IBD | Oct. 24, 2014 | 13:23PM EST
  21. Stocks Flat In Mixed Volume; Amazon.com Weighs On Techs

    IBD | Oct. 24, 2014 | 10:52AM EST
  22. UPDATE: Bristol-Myers Squibb Q3 Earnings Top Estimates

    Benzinga | Oct. 24, 2014 | 08:59AM EST
  23. Stock Futures Aim For Flat Open; Amazon.com Crumples On Q3 Miss

    IBD | Oct. 24, 2014 | 08:58AM EST
  24. #PreMarket Primer: Friday, October 24: Ebola Fears Weigh On Markets

    Benzinga | Oct. 24, 2014 | 07:47AM EST
  25. Earnings Scheduled For October 24, 2014

    Benzinga | Oct. 24, 2014 | 04:51AM EST
  26. Must Watch Stocks for Today

    Benzinga | Oct. 24, 2014 | 04:06AM EST
  27. Stocks Rebound; Amazon.com Slides After Hours

    IBD | Oct. 23, 2014 | 17:02PM EST
  28. Drug ETFs Attractive Buys On Pullback

    Benzinga | Oct. 22, 2014 | 17:10PM EST
  29. Weekly CFO Sells Highlight: Williams Companies Inc, Google Inc, Bristol-Myers Squibb Company

    GuruFocus | Oct. 19, 2014 | 14:09PM EST
  30. Benzinga Weekly Preview: Earnings Season Is In Full Swing

    Benzinga | Oct. 19, 2014 | 10:19AM EST
  31. Apple Leads the Charge as Earnings Season Heats Up

    FoxBusiness | Oct. 17, 2014 | 16:48PM EST
  32. The Six Types of Winning Stocks

    GuruFocus | Oct. 17, 2014 | 14:38PM EST
  33. Markets Debut Week On Negative Note; S&P 500 Falls Through Key Level

    Benzinga | Oct. 13, 2014 | 16:57PM EST
  34. Merck to release hep C data

    IBD | Oct. 8, 2014 | 18:38PM EST
  35. Merck, Bristol, Arrowhead Prep Hepatitis Studies

    IBD | Oct. 8, 2014 | 13:36PM EST
  36. Salix, Actavis Among Big Cap Pharmas In Merger Mambo

    IBD | Oct. 7, 2014 | 19:33PM EST
  37. Bristol-Myers pulls FDA filing

    IBD | Oct. 7, 2014 | 18:49PM EST
  38. Bristol-Myers Pulls FDA Filing For 2-Drug Hep C Combo

    IBD | Oct. 7, 2014 | 11:13AM EST
  39. Bristol-Myers Squibb Statement About Asunaprevir In The US, WIthdraws NDA

    Benzinga | Oct. 7, 2014 | 08:32AM EST
  40. 2 Mutual Funds Holding Hospital Stocks

    Benzinga | Oct. 6, 2014 | 10:38AM EST
  41. NeurOp Receives Milestone Payment As Bristol-Myers Squibb Nominates NMDA Receptor Compound As Candidate For Drug Development

    Benzinga | Oct. 2, 2014 | 15:16PM EST
  42. Morgan Stanley Believes Bristol-Myers Squibb Co. Could Move Significantly Over Next Several Months

    Benzinga | Oct. 2, 2014 | 10:15AM EST
  43. Gilead's New HIV Drug Key To Long-Term Strategy

    IBD | Sep. 24, 2014 | 17:29PM EST
  44. Gilead OKs Generic Sovaldi To Expand Global Access

    IBD | Sep. 15, 2014 | 11:35AM EST
  45. Bristol-Myers Squibb Co In Patent Suit Vs. Merck & Co., Inc. Over Skin Cancer Drug

    Benzinga | Sep. 5, 2014 | 16:04PM EST
  46. Merck PD-1 Inhibitor Approved For Skin Cancer

    IBD | Sep. 4, 2014 | 16:33PM EST
  47. Drug M&A Boom Driven By Long-Term Trends: PwC

    IBD | Sep. 3, 2014 | 16:22PM EST
  48. Booming Biotech Market Benefits REIT BioMed Realty

    IBD | Sep. 2, 2014 | 17:42PM EST
  49. Bristol-Myers: Absolute Valuation Model versus Relative Valuation Model

    GuruFocus | Aug. 29, 2014 | 11:04AM EST
  50. Bristol-Myers Drug Gets OK

    IBD | Aug. 27, 2014 | 18:56PM EST
Trading Center